Doctors providing check-ups with a sign announcing free annual health checks and expanded insurance. Vietnam Sets Ambitious 2026 Plan for Free Annual Health Checks, Expanded Coverage, and System-Wide Reform Vietnam is preparing to deliver one of its most far-reaching public-health reforms in decades, a nationwide guarantee of one free annual health check or screening for … Read more
Novo Nordisk has introduced a $199 introductory price for Wegovy and Ozempic starter doses, alongside a permanent drop in monthly self-pay costs to $349.
The UK and ABPI have agreed to a third extension of the VPAG withdrawal deadline, moving it to December 16, 2025.
Spanish health official displays a Ministry of Health certificate for asbestos-related injury, as Spain rolls out its new national certification system alongside expanded neonatal screening reforms. (Editorial illustration.) CISNS approves sweeping updates to neonatal diagnostics and formalizes a nationwide system to certify asbestos-related disease for compensation Spain’s Interterritorial Council of the National Health System (CISNS) … Read more
The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining its plans to assess the long-term clinical and economic value of updated COVID-19 vaccines.
Sweden’s TLV has published its health economic assessment of Merck’s Keytruda for locally advanced cervical cancer, finding clear efficacy benefits when added to chemoradiation. However, the agency warns that cost-effectiveness hinges on price transparency and real-world survival durability.
CMS’ Medicaid drug payment model links value-based pricing and international benchmarks to lower costs and improve patient outcomes. (Editorial illustration.) US government aims to lower Medicaid drug prices and align costs with global rates under new GENEROUS model The US government has launched a sweeping initiative to reduce prescription drug costs under the Medicaid program, … Read more
The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.
Thailand is letting patients fill hospital prescriptions at registered pharmacies under a new initiative expected to save households 32 billion baht annually. Officials say the program will ease private-sector pricing pressure and improve drug access nationwide.
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.